[无可用内容]。 - Suppr | 超能文献

[Not Available].

作者信息

Ravasio Roberto, Marcellusi Andrea, de Nicola Luca

机构信息

HEOR and RWE Lead, CENCORA PharmaLex Italy S.p.A., Milano - Italy.

Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Milano - Italy.

出版信息

Glob Reg Health Technol Assess. 2024 Dec 2;11:231-238. doi: 10.33393/grhta.2024.3309. eCollection 2024 Jan-Dec.

DOI:10.33393/grhta.2024.3309

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11615928/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db2c/11615928/3bfc5efeb2fd/grhta-11-231_g001.jpg

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

[Not Available].[无可用内容]。

Glob Reg Health Technol Assess. 2024 Dec 2;11:231-238. doi: 10.33393/grhta.2024.3309. eCollection 2024 Jan-Dec.

本文引用的文献

1

Chronic Kidney Disease Eligible for SGLT2 Inhibitors Through the Integration of Italian Administrative and Primary Care Data.通过整合意大利行政和初级保健数据，确定适合 SGLT2 抑制剂的慢性肾脏病。

G Ital Nefrol. 2024 Jun 28;41(3):2024-vol3. doi: 10.69097/41-03-2024-08.

2

Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis.将达格列净在慢性肾脏病中的疗效转化为降低医疗资源利用和成本：一项医疗成本抵消分析。

J Med Econ. 2023 Jan-Dec;26(1):1407-1416. doi: 10.1080/13696998.2023.2264715. Epub 2023 Oct 31.

3

Dapagliflozin versus empagliflozin in patients with chronic kidney disease.达格列净与恩格列净治疗慢性肾脏病患者的比较

Front Pharmacol. 2023 Aug 4;14:1227199. doi: 10.3389/fphar.2023.1227199. eCollection 2023.

4

Short-term costs in patients with chronic kidney disease treated with dapagliflozin: a retrospective cohort study.达格列净治疗慢性肾脏病患者的短期成本：一项回顾性队列研究。

Expert Rev Pharmacoecon Outcomes Res. 2023 Jul-Dec;23(9):1057-1066. doi: 10.1080/14737167.2023.2237679. Epub 2023 Aug 4.

5

Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective.在慢性肾脏病人群中扩大格列净覆盖范围的预算影响分析：法国视角。

Adv Ther. 2023 Sep;40(9):3751-3769. doi: 10.1007/s12325-023-02574-2. Epub 2023 Jun 21.

6

Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial.达格列净在北美和南美慢性肾脏病黑种人与白种人患者中的有效性和安全性：一项随机临床试验的二次分析

JAMA Netw Open. 2023 Apr 3;6(4):e2310877. doi: 10.1001/jamanetworkopen.2023.10877.

7

Projecting the Epidemiological and Economic Impact of Chronic Kidney Disease Using Patient-Level Microsimulation Modelling: Rationale and Methods of Inside CKD.利用基于患者水平的微观模拟模型预测慢性肾脏病的流行病学和经济影响：Inside CKD 的原理和方法。

Adv Ther. 2023 Jan;40(1):265-281. doi: 10.1007/s12325-022-02353-5. Epub 2022 Oct 28.

8

Epidemiology of chronic kidney disease: an update 2022.慢性肾脏病流行病学：2022年最新情况

Kidney Int Suppl (2011). 2022 Apr;12(1):7-11. doi: 10.1016/j.kisu.2021.11.003. Epub 2022 Mar 18.

9

Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions.达格列净在不同主要地理区域慢性肾脏病患者中的疗效与安全性。

Kidney Int Rep. 2022 Feb 2;7(4):699-707. doi: 10.1016/j.ekir.2022.01.1060. eCollection 2022 Apr.

10

Hypertension and cardiovascular risk factor management in a multi-ethnic cohort of adults with CKD: a cross sectional study in general practice.在一个多民族的慢性肾脏病成人队列中进行的高血压和心血管风险因素管理：一般实践中的横断面研究。

J Nephrol. 2022 Apr;35(3):901-910. doi: 10.1007/s40620-021-01149-0. Epub 2021 Nov 16.